Donoghue Forlines LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 28.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,493 shares of the company’s stock after selling 2,563 shares during the quarter. Donoghue Forlines LLC’s holdings in Johnson & Johnson were worth $1,006,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in JNJ. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $35,000. Dark Forest Capital Management LP grew its position in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $45,000. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $52,000. 67.57% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on JNJ. Raymond James lifted their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a report on Monday, July 24th. Citigroup began coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a report on Friday, July 21st. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $171.80.
Johnson & Johnson Stock Performance
JNJ stock opened at $173.85 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The company has a 50 day moving average price of $164.90 and a 200 day moving average price of $161.14. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The stock has a market capitalization of $451.83 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 2.92 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the previous year, the company posted $2.59 EPS. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.74%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock worth $7,928,856. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 8/7 – 8/11
- What is the S&P/TSX Index?
- 3 Retailers To Watch Closely Next Week
- How to Buy Gold Stock and Invest in Gold
- Investing in Coffee: 3 Great Strategies to Consider
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
